Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17131943 | MATERIALS AND METHODS FOR BLADDER CANCER DETECTION | December 2020 | January 2024 | Abandon | 37 | 1 | 1 | No | No |
| 17116067 | MUCOSAL HEALING PROMOTER | December 2020 | May 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17113773 | Morpholino Oligonucleotides Useful In Cancer Treatment | December 2020 | February 2023 | Allow | 26 | 1 | 0 | No | No |
| 17059198 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DENTIN-DENTAL PULP DISEASE OR PERIODONTAL DISEASE, CONTAINING LPAR2 INHIBITOR | November 2020 | April 2024 | Allow | 41 | 2 | 1 | No | No |
| 16953950 | METHODS FOR INCREASING PLATELET COUNT BY INHIBITING BILIVERDIN IXBETA REDUCTASE | November 2020 | April 2023 | Abandon | 29 | 1 | 0 | Yes | No |
| 17057525 | FUNCTIONAL NUCLEIC ACID HAVING NUCLEOSIDE ANALOG DRUG INTEGRATED INTO SKELETON, DERIVATIVE AND USE THEREOF | November 2020 | July 2024 | Abandon | 44 | 2 | 1 | No | No |
| 17056824 | MYOCARDIAL DYSFUNCTION THERAPEUTIC AGENT | November 2020 | October 2022 | Abandon | 23 | 0 | 1 | No | No |
| 17096615 | METHODS FOR TREATING NLRP3 INFLAMMASOME-ASSOCIATED DISEASES, AND METHODS OF IDENTIFYING AGENTS USEFUL THEREFOR | November 2020 | December 2022 | Allow | 25 | 1 | 0 | No | No |
| 17094903 | Medicinal composition comprising a non-coding RNA molecule and an antibody targeting a tumor antigen | November 2020 | February 2024 | Allow | 39 | 3 | 1 | Yes | No |
| 17093892 | ANTISENSE OLIGONUCLEOTIDES USEFUL IN TREATMENT OF POMPE DISEASE | November 2020 | July 2023 | Allow | 32 | 2 | 0 | No | No |
| 17091693 | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | November 2020 | January 2023 | Allow | 26 | 1 | 0 | No | No |
| 17052916 | Blockade of miR466l-3p binding to IL-17A mRNA with site-specific target site blocker prevents neuro-inflammatory-mediated disease | November 2020 | December 2022 | Allow | 25 | 1 | 1 | Yes | No |
| 17052435 | FORMULATION | November 2020 | October 2022 | Allow | 24 | 1 | 1 | No | No |
| 17085841 | MODULATING SYNGAP | October 2020 | October 2022 | Allow | 24 | 1 | 1 | No | No |
| 17080240 | METHODS FOR THE IN VIVO PRODUCTION OF SINGLE STRANDED DNA AND USES THEREOF | October 2020 | September 2024 | Abandon | 47 | 2 | 1 | No | No |
| 17075440 | METHODS AND COMPOSITIONS OF INSECT CONTROL | October 2020 | December 2022 | Abandon | 26 | 0 | 1 | No | No |
| 17071473 | TWO-TAILED SELF-DELIVERING SIRNA | October 2020 | March 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 17069907 | GLUCOKINASE (GCK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | October 2020 | August 2023 | Allow | 34 | 1 | 1 | No | No |
| 17068185 | MODULATION OF HUNTINGTIN EXPRESSION | October 2020 | April 2022 | Allow | 18 | 0 | 0 | No | No |
| 17046380 | SIRT1-SARNA COMPOSITIONS AND METHODS OF USE | October 2020 | September 2022 | Allow | 24 | 1 | 1 | No | No |
| 17038425 | RNA Interactome of Polycomb Repressive Complex 1 (PRC1) | September 2020 | January 2023 | Abandon | 28 | 1 | 1 | No | No |
| 17041843 | SPLICE-SWITCHING OLIGONUCLEOTIDES AND METHODS OF USE | September 2020 | May 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 17041148 | NUCLEIC ACID MOLECULES FOR PSEUDOURIDYLATION | September 2020 | May 2023 | Allow | 31 | 2 | 1 | No | No |
| 16982274 | NUCLEIC ACID WITH REDUCED TOXICITY | September 2020 | August 2023 | Allow | 35 | 3 | 0 | Yes | No |
| 16982167 | ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF | September 2020 | January 2023 | Allow | 28 | 1 | 2 | No | No |
| 16982467 | 2'F-ANA-LET7 MEDIATED UTROPHIN UPREGULATION FOR DMD THERAPY | September 2020 | May 2024 | Allow | 44 | 3 | 1 | No | No |
| 17025239 | Modulators of APOL1 Expression | September 2020 | August 2022 | Allow | 22 | 1 | 1 | No | No |
| 17024624 | COMPOSITIONS AND METHODS OF TREATING MUSCLE ATROPHY AND MYOTONIC DYSTROPHY | September 2020 | September 2021 | Allow | 12 | 2 | 1 | No | No |
| 17022409 | Nucleic Acid Compounds for Binding Growth Differentiation Factor 11 | September 2020 | August 2022 | Allow | 23 | 1 | 1 | No | No |
| 17020879 | METHODS AND COMPOSITIONS FOR TREATING CANCERS USING ANTISENSE | September 2020 | June 2023 | Allow | 33 | 3 | 0 | Yes | No |
| 17021510 | Compounds and Methods for the Modulation of Proteins | September 2020 | February 2024 | Allow | 41 | 4 | 0 | Yes | No |
| 17020355 | IMMUNE MODULATION WITH TLR9 AGONISTS FOR CANCER TREATMENT | September 2020 | August 2023 | Abandon | 35 | 2 | 1 | Yes | No |
| 17020498 | Novel System for the Biocontrol of White Spot Syndrome Virus (WSSV) in Aquaculture | September 2020 | June 2022 | Allow | 21 | 1 | 1 | No | No |
| 16980191 | NUCLEIC ACID COMPLEX | September 2020 | October 2022 | Allow | 25 | 1 | 1 | No | No |
| 16977649 | COMPOUNDS AND METHODS FOR THE MODULATION OF AMYLOID-BETA PRECURSOR PROTEIN | September 2020 | March 2023 | Allow | 31 | 3 | 0 | No | No |
| 17006675 | HIGH-EFFICIENCY TRANSFECTION OF BIOLOGICAL CELLS USING SONOPORATION | August 2020 | August 2021 | Allow | 11 | 1 | 1 | No | No |
| 17005213 | COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT | August 2020 | August 2022 | Abandon | 23 | 0 | 1 | No | No |
| 16975700 | NEURODEGENERATIVE DISORDERS | August 2020 | November 2022 | Allow | 27 | 2 | 1 | Yes | No |
| 16998046 | POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF | August 2020 | December 2021 | Abandon | 16 | 3 | 0 | No | No |
| 16998259 | DRY POWDER COMPOSITION COMPRISING LONG-CHAIN RNA | August 2020 | February 2022 | Allow | 18 | 2 | 1 | No | No |
| 16997022 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF | August 2020 | July 2022 | Abandon | 23 | 0 | 1 | No | No |
| 16995224 | LYOPHILIZATION OF RNA | August 2020 | March 2022 | Allow | 18 | 1 | 1 | No | No |
| 16994230 | TARGETED TRANS-SPLICING USING CRISPR/CAS13 | August 2020 | July 2023 | Allow | 35 | 2 | 1 | Yes | No |
| 16968701 | MODIFIED COMPOUNDS AND USES THEREOF | August 2020 | December 2021 | Allow | 16 | 1 | 0 | Yes | No |
| 16988226 | INTERFERING RNA MOLECULES | August 2020 | September 2022 | Allow | 26 | 1 | 1 | No | No |
| 16942386 | HSD17B13 VARIANTS AND USES THEREOF | July 2020 | June 2022 | Allow | 22 | 1 | 1 | No | No |
| 16941303 | VARIANT RNAi | July 2020 | June 2023 | Allow | 34 | 1 | 2 | No | No |
| 16938274 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | July 2020 | June 2022 | Allow | 23 | 1 | 0 | No | No |
| 16938278 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | July 2020 | January 2022 | Allow | 18 | 1 | 0 | No | No |
| 16947126 | Compositions and Methods for the Systemic Treatment of Arthritis | July 2020 | March 2022 | Allow | 20 | 2 | 1 | No | No |
| 15733391 | OLIGONUCLEOTIDES FOR MODULATING ERC1 EXPRESSION | July 2020 | July 2022 | Abandon | 23 | 0 | 1 | No | No |
| 15733392 | ANTISENSE OLIGONUCLEOTIDES TARGETING SREBP1 | July 2020 | July 2022 | Abandon | 23 | 0 | 1 | No | No |
| 16927559 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE | July 2020 | April 2022 | Abandon | 21 | 1 | 0 | No | No |
| 15733367 | OLIGONUCLEOTIDES FOR MODULATING PIAS4 EXPRESSION | July 2020 | February 2023 | Abandon | 31 | 0 | 1 | No | No |
| 16961624 | ANTISENSE OLIGONUCLEOTIDES TARGETING ALPHA-SYNUCLEIN AND USES THEREOF | July 2020 | January 2022 | Allow | 18 | 1 | 0 | No | No |
| 15733369 | ALPHA-SYNUCLEIN ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF | July 2020 | February 2023 | Abandon | 31 | 0 | 1 | No | No |
| 15733368 | OLIGONUCLEOTIDES FOR MODULATING GSK3B EXPRESSION | July 2020 | April 2022 | Abandon | 21 | 0 | 1 | No | No |
| 16958969 | REDUCING BETA-CATENIN AND IDO EXPRESSION TO POTENTIATE IMMUNOTHERAPY | June 2020 | June 2023 | Allow | 36 | 1 | 1 | No | No |
| 16905719 | EXOSOME TRANSFER OF NUCLEIC ACIDS TO CELLS | June 2020 | February 2024 | Abandon | 44 | 0 | 1 | No | No |
| 16904993 | DRY POWDER COMPOSITION COMPRISING LONG-CHAIN RNA | June 2020 | January 2022 | Allow | 19 | 1 | 1 | No | No |
| 16902198 | SELF-REPLICATING CELL SELECTIVE GENE DELIVERY COMPOSITIONS, METHODS, AND USES THEREOF | June 2020 | September 2021 | Abandon | 15 | 2 | 1 | No | No |
| 16896752 | ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS | June 2020 | May 2023 | Allow | 35 | 2 | 0 | No | No |
| 16770877 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS OF GENOMIC IMPRINTING | June 2020 | February 2024 | Allow | 44 | 3 | 1 | Yes | No |
| 16894648 | UNA AMIDITES AND USES THEREOF | June 2020 | December 2023 | Allow | 42 | 1 | 1 | No | No |
| 16892995 | CTLA-4 APTAMER CONJUGATES | June 2020 | July 2021 | Allow | 14 | 2 | 1 | No | No |
| 16891155 | POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF | June 2020 | September 2022 | Abandon | 27 | 1 | 1 | No | No |
| 16883667 | COMPOSITIONS AND METHODS OF INHIBITING GENE EXPRESSION IN A LUNG | May 2020 | May 2022 | Allow | 23 | 1 | 1 | Yes | No |
| 16881430 | ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF | May 2020 | January 2021 | Allow | 7 | 1 | 0 | No | No |
| 16878672 | NOVEL VIRAL COMPLEX COMPRISING shRNA and anti-EpCAM ANTIBODY AND USES THEREOF | May 2020 | September 2022 | Allow | 28 | 1 | 0 | No | No |
| 16869812 | METHOD OF FIXING AND EXPRESSING PHYSIOLOGICALLY ACTIVE SUBSTANCE | May 2020 | July 2022 | Allow | 26 | 1 | 0 | No | No |
| 16762580 | CRISPR/CAS Systems For Treatment of DMD | May 2020 | October 2022 | Abandon | 29 | 0 | 1 | No | No |
| 16762734 | METHODS OF MODULATING ANTISENSE ACTIVITY | May 2020 | May 2022 | Abandon | 24 | 1 | 0 | No | No |
| 16762444 | SELF-INACTIVATING (SIN) CRISPR/CAS OR CRISPR/CPF1 SYSTEMS AND USES THEREOF | May 2020 | January 2024 | Allow | 44 | 2 | 1 | No | No |
| 16759610 | INTEGRIN LIGANDS AND USES THEREOF | April 2020 | September 2022 | Allow | 29 | 1 | 3 | Yes | No |
| 16758205 | ANTISENSE ANTIBACTERIAL COMPOUNDS AND METHODS | April 2020 | March 2022 | Abandon | 23 | 0 | 1 | No | No |
| 16852933 | OLIGOMERS | April 2020 | November 2020 | Allow | 7 | 1 | 1 | Yes | No |
| 16848968 | COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN | April 2020 | March 2021 | Allow | 11 | 1 | 0 | Yes | No |
| 16849583 | COMPOSITIONS FOR MODULATING SOD-1 EXPRESSION | April 2020 | November 2020 | Allow | 7 | 1 | 0 | Yes | No |
| 16755544 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | April 2020 | October 2022 | Allow | 30 | 1 | 1 | No | No |
| 16754805 | ANTISENSE OLIGOMER COMPOUNDS | April 2020 | September 2022 | Allow | 29 | 1 | 1 | No | No |
| 16844475 | ENGINEERED PRODUCER CELL LINES AND METHODS OF MAKING AND USING THE SAME | April 2020 | March 2024 | Allow | 47 | 2 | 1 | Yes | No |
| 16844785 | DELIVERY METHOD OF TARGET MATERIAL INTO EXTRACELLULAR VESICLES USING EXTRACORPOREAL SHOCKWAVE | April 2020 | December 2020 | Allow | 8 | 1 | 1 | No | No |
| 16840513 | Methods and Compositions for Treating Obesity | April 2020 | June 2022 | Allow | 26 | 1 | 1 | No | No |
| 16841259 | COMPOSITIONS AND METHODS TO TREATING HEMOGLOBINOPATHIES | April 2020 | May 2021 | Allow | 13 | 1 | 1 | No | No |
| 16836213 | Antisense Oligonucleotides (ODN) Against SMAD7 and Uses Thereof in Medical Field | March 2020 | August 2021 | Abandon | 16 | 1 | 1 | No | No |
| 16835386 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS | March 2020 | February 2022 | Allow | 23 | 2 | 1 | Yes | No |
| 16651458 | OLIGONUCLEOTIDE INHIBITING THE EXPRESSION OF CHOP | March 2020 | May 2023 | Allow | 37 | 3 | 1 | No | No |
| 16828053 | METHODS RELATING TO LUNG CANCER | March 2020 | April 2022 | Allow | 25 | 2 | 1 | Yes | No |
| 16823634 | Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) Inhibitors | March 2020 | July 2022 | Allow | 28 | 2 | 1 | No | No |
| 16823832 | Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Protein Cleavage-Activating Protein (SCAP) Inhibitors | March 2020 | January 2022 | Allow | 22 | 1 | 1 | No | No |
| 16821384 | CRISPR/CAS DROPOUT SCREENING PLATFORM TO REVEAL GENETIC VULNERABILITIES ASSOCIATED WITH TAU AGGREGATION | March 2020 | May 2023 | Allow | 38 | 1 | 1 | No | No |
| 16647721 | FUNCTIONAL NUCLEIC ACID MOLECULE AND USE THEREOF | March 2020 | September 2022 | Allow | 30 | 1 | 1 | No | No |
| 16818337 | METHOD FOR DETECTING RP2-ARHGAP6 GENE | March 2020 | January 2022 | Abandon | 23 | 1 | 0 | No | No |
| 16818599 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | March 2020 | March 2021 | Allow | 12 | 0 | 1 | Yes | No |
| 16813087 | RNA NANOPARTICLES FOR BRAIN TUMOR TREATMENT | March 2020 | October 2021 | Allow | 19 | 1 | 0 | No | No |
| 16644977 | Double-stranded RNA Molecule Targeting CKIP-1 and Use Thereof | March 2020 | July 2021 | Allow | 16 | 1 | 1 | No | No |
| 16645012 | HNF4A SARNA COMPOSITIONS AND METHODS OF USE | March 2020 | June 2021 | Allow | 16 | 1 | 1 | No | No |
| 16645014 | STABILIZED HNF4A SARNA COMPOSITIONS AND METHODS OF USE | March 2020 | May 2022 | Allow | 26 | 1 | 1 | No | No |
| 16804215 | CANCER TREATMENT | February 2020 | January 2022 | Abandon | 23 | 1 | 0 | No | No |
| 16803006 | Enhancing Health in Mammals Using Telomerase Reverse Transcriptase Gene Therapy | February 2020 | May 2021 | Allow | 15 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHONG, KIMBERLY.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 10.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CHONG, KIMBERLY works in Art Unit 1635 and has examined 894 patent applications in our dataset. With an allowance rate of 52.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 28 months.
Examiner CHONG, KIMBERLY's allowance rate of 52.5% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHONG, KIMBERLY receive 1.62 office actions before reaching final disposition. This places the examiner in the 29% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by CHONG, KIMBERLY is 28 months. This places the examiner in the 66% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +31.9% benefit to allowance rate for applications examined by CHONG, KIMBERLY. This interview benefit is in the 79% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 27.0% of applications are subsequently allowed. This success rate is in the 49% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 58.5% of cases where such amendments are filed. This entry rate is in the 85% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 70.6% of appeals filed. This is in the 57% percentile among all examiners. Of these withdrawals, 83.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 59.4% are granted (fully or in part). This grant rate is in the 61% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 2.0% of allowed cases (in the 75% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.0% of allowed cases (in the 75% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.